Dr Reddy’s Laboratories (RDY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr. Reddy’s Laboratories has launched Toripalimab in India, marking it as the first immuno-oncology drug approved for nasopharyngeal carcinoma (NPC) in the country. This launch positions India as the third nation globally to access this innovative treatment, following China and the U.S. Toripalimab has demonstrated a 48% reduction in disease progression risk when combined with standard chemotherapy, addressing a significant need for advanced NPC treatment.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.